Credent and CardioTech strike technology deal:
This article was originally published in Clinica
Medical device company Credent has struck a $500,000 technology transfer and licensing deal with Woburn, Massachusetts-based CardioTech International. The exclusive deal, which enables Credent to synthesise Chronoflex RC biodurable polycarbonate-urethane, also involves CardioTech retaining certain rights to Chronoflex RC for the manufacture and marketing of coronary artery bypass grafts. Credent, based in Wrexham, Wales, will use the technology in its current vascular access and peripheral vascular grafts range and in new products.
You may also be interested in...
Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.